4733315
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study

Document
type: Class

Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study
type: Entity
related by: 4733315
type: Continuant
type: Article
type: Information Content Entity
type: Document
type: Thing
language: Inglese
most specific type: Conference Paper
type: Generically Dependent Continuant
type: Conference Paper

Continuant
type: Class

Inglese
type: Language

Entity
type: Class

Generically Dependent Continuant
type: Class

individual
rights: termsOfUse
date: 2026-08-27T06:56:41
publisher: Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study
type: Document
label: RDF description of Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study - http://irises.unibs.it/resource/item/59099

Article
type: Class

Information Content Entity
type: Class

Conference Paper
type: Class